

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EV 706064119 US

Express Mail Label Number

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

Art Unit: 1756

SUTTON ET AL.

Examiner: Lao, Marialouisa

APPLICATION NO: 10/507.255

FILED: 09/28/04

FOR: SALTS OF NATEGLINIDE

MS: After Final

Commissioner for Patents

PO Box 1450

Alexandria, VA 22313-1450

NOTICE OF APPEAL PETITION FOR EXTENSION OF TIME

Sir:

The period for filing a Notice of Appeal has a shortened statutory time set to expire on April 30, 2008. A three-month extension is hereby requested pursuant to 37 CFR §1.136(a).

Please charge Deposit Account No. 19-0134 in the name of Novartis in the amount of \$1050 for payment of the extension fee. An additional copy of this paper is here enclosed. The Commissioner is hereby authorized to charge any additional fees under 37 CFR §1.17 which may be required, or credit any overpayment, to Account No. 19-0134 in the name of Novartis.

Respectfully submitted,

Novartis Pharmaceuticals Corp. Patents Pharma One Health Plaza, Building 104

East Hanover, NJ 07936-1080

July 9, 2008

Jennifer C. Chapman Attorney for Applicants

Reg. No. 47,487

Phone No. (862) 778-1202

07/11/2008 HGEBREN1 00000047 190134 10507255

02 FC:1253

1050.00 DA



FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

Express Mail Label Number

Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

Art Unit: 1756

SUTTON ET AL.

Examiner: Lao, Marialouisa

APPLICATION NO: 10/507,255

FILED: 09/28/04

FOR: SALTS OF NATEGLINIDE

MS: After Final Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

NOTICE OF APPEAL PETITION FOR EXTENSION OF TIME

Sir:

The period for filing a Notice of Appeal has a shortened statutory time set to expire on April 30, 2008. A three-month extension is hereby requested pursuant to 37 CFR §1.136(a).

Please charge Deposit Account No. 19-0134 in the name of Novartis in the amount of \$1050 for payment of the extension fee. An additional copy of this paper is here enclosed. The Commissioner is hereby authorized to charge any additional fees under 37 CFR §1.17 which may be required, or credit any overpayment, to Account No. 19-0134 in the name of Novartis.

Respectfully submitted,

Novartis Pharmaceuticals Corp. Patents Pharma One Health Plaza, Building 104 East Hanover, NJ 07936-1080

July 9, 2008

Attorney for Applicants

Reg. No. 47,487

Phone No. (862) 778-1202